Review of plasmapheresis treatments (TPE) using multiFiltratePRO
Part of Immune system & allergy clinical trials.
This study looks back at the medical records of people who had plasmapheresis (TPE) treatment to learn more about how it works. If you had this treatment between 2019 and 2023, researchers may use your data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh at least 40 kg (about 88 pounds).
- Your doctor prescribed plasmapheresis as part of your treatment, following standard guidelines.
- You received plasmapheresis between January 2019 and October 2023.
- Your medical records include at least half of the key details (like lab results and treatment information) from those sessions.
- You did not take part in another experimental study during the same period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new plasma filter, PX2, used in a procedure called therapeutic plasma exchange (TPE) to clean harmful substances from your blood. It’s for people who already need TPE and can safely use a blood thinner during the treatment.
This study tests a special blood filtration machine (multiFiltratePRO) in children with kidney failure who need continuous dialysis. It aims to see how well the treatment works and if it's safe for younger patients.
This study looks at whether removing and replacing blood plasma (called therapeutic plasma exchange or TPE) can help people with immune-related nerve or brain conditions. It includes both new and returning cases that meet standard guidelines for this treatment.
This trial tests whether a procedure called therapeutic plasma exchange (TPE) — which cleans harmful substances from your blood — is more effective than standard medicines for treating severe autoimmune hepatitis. It may be an option if your condition is very serious and you are not able to get a liver transplant within the next month.
This study looks at how a procedure called therapeutic plasma exchange (TPE), which filters the blood, affects the levels of immunotherapy (immune checkpoint inhibitor) drugs in the body. It aims to help manage severe side effects from these cancer treatments.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.